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Abstract
Background: A combination of levodopa (L-DOPA) and carbidopa is the most commonly-used treatment for symptom
management in Parkinson’s disease. Studies have shown that concomitant use of a COMT inhibitor is highly beneficial in
controlling the wearing-off phenomenon by improving L-DOPA bioavailability as well as brain entry. The present study
sought to determine whether (-)-epigallocatechin-3-gallate (EGCG), a common tea polyphenol, can serve as a naturally-
occurring COMT inhibitor that also possesses neuroprotective actions.
Methodology/Principal Findings: Using both in vitro and in vivo models, we investigated the modulating effects of EGCG
on L-DOPA methylation as well as on chemically induced oxidative neuronal damage and degeneration. EGCG strongly
inhibited human liver COMT-mediated O-methylation of L-DOPA in a concentration-dependent manner in vitro, with an
average IC50 of 0.36 mM. Oral administration of EGCG moderately lowered the accumulation of 3-O-methyldopa in the
plasma and striatum of rats treated with L-DOPA + carbidopa. In addition, EGCG also reduced glutamate-induced oxidative
cytotoxicity in cultured HT22 mouse hippocampal neuronal cells through inactivation of the nuclear factor kB-signaling
pathway. Under in vivo conditions, administration of EGCG exerted a strong protective effect against kainic acid-induced
oxidative neuronal death in the hippocampus of rats.
Conclusions/Significance: These observations suggest that oral administration of EGCG may have significant beneficial
effects in Parkinson’s patients treated with L-DOPA and carbidopa by exerting a modest inhibition of L-DOPA methylation
plus a strong neuroprotection against oxidative damage and degeneration.
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Introduction
Parkinson’s disease (PD) is a chronic and progressive neurolog-
ical disorder characterized by uncontrolled muscle tremor,
rigidity, and bradykinesia. Despite decades of research, at present
there is still no cure for the disease. Most of the available therapies
will only alleviate the symptoms but will not halt the progression of
the disease [1,2]. Among the currently-used drug treatments for
PD, levodopa (L-DOPA), a precursor used in the body for
biosynthesis of dopamine, is still considered the most effective drug
for relieving motor symptoms. L-DOPA is almost always used in
combination with a peripheral dopa decarboxylase inhibitor (such
as carbidopa or benserazide), and sometimes a catecholamine-O-
methyltransferase (COMT) inhibitor (such as tolcapone or
entacapone) is also added. While the peripheral dopa decarbox-
ylase inhibitor would effectively prevent the rapid conversion of L-
DOPA to dopamine in peripheral tissues, a COMT inhibitor
would further prevent it from metabolic conversion (catalyzed by
COMT) to form 3-O-methyldopa (3-OMD) [3]. Studies have
shown that the use of a COMT inhibitor is particularly helpful in
controlling the wearing-off phenomenon in PD patients by
prolonging the circulating half-life of L-DOPA and improving its
brain entry [4]. When this multi-drug combination strategy is
used, the effective dose of L-DOPA is reduced, and so are some of
the untoward effects that are likely exerted by L-DOPA
metabolites, such as dopamine and 3-OMD [5]. Presently,
tolcapone and entacapone are the two COMT inhibitors
approved for clinical use for enhancement of therapeutic benefits
of L-DOPA. However, the use of tolcapone is only limited to
fluctuating patients who are refractory to other therapies, and
requires heightened monitoring for the occurrence of hepatotox-
icity. Although entacapone is relatively safer, it appears less
efficacious than tolcapone [6–8].
In the present study, we sought to determine whether (-)-
epigallocatechin-3-gallate (EGCG), a well-known and quantita-
tively-major tea polyphenol with many health-promoting benefi-
cial effects [9,10], can serve as a naturally-occurring, safer COMT
inhibitor that also possesses neuroprotective actions (see Figure 1).
This idea was proposed on the basis of the following consider-
ations: First, some of the catechol-containing bioflavonoids and tea
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[11]. In addition, it was shown previously that bioflavonoids and
tea catechins, e.g.,( +)-catechin, (-)-epicatechin and EGCG, are also
strong inhibitors of the human liver COMT-mediated O-
methylation of endogenous catechol estrogens [12]. Among these
dietary compounds, EGCG was found to be the most potent
inhibitor, with an IC50 of approximately 0.1 mM when 2-
hydroxyestradiol was used as substrate [12]. Secondly, oxidative
stress and neuronal damage have been considered an important
etiological factor in the pathogenesis of PD as well as in the
development of adverse effects associated with the long-term use of
L-DOPA in PD patients [13,14]. Tea catechins, especially EGCG,
are well-known scavengers of reactive oxygen species (ROS), and
they may also function as antioxidants through modulation of
transcriptional factors and enzyme activities [9,15]. It is, therefore,
possible that EGCG may be a dietary antioxidant that can be used
clinically in PD patients to inhibit COMT-mediated metabolic
disposition of L-DOPA while also exerting neuroprotective
actions. This intriguing possibility was experimentally examined
in the present study. The findings of this study may also shed a
mechanistic light on the recent epidemiological observation
suggesting that regular tea drinking is associated with a reduced
risk of PD [16,17].
Results
In vitro inhibition of L-DOPA methylation
We first optimized the reaction conditions for the in vitro O-
methylation of L-DOPA by determining the effect of variable
incubation time and the effect of variable enzyme concentration.
The cytosolic COMT prepared from three representative human
liver samples (HL4C, HL8C, and HL9C) was used in this study,
and a representative data set obtained with HL4C was shown in
Figure 2. The rate of O-methylation of L-DOPA was dependent
on the incubation time (linear up to 30 min, Figure 2A), cytosolic
protein concentration (linear up to 0.5 mg/mL, Figure 2B), and
[
3H-methyl]AdoMet concentration (Figure 2C). The dependence
of O-methylation on [
3H-methyl]AdoMet concentration followed
the typical Michaelis-Menten kinetics, with an apparent Km value
of approximately 50 mM (calculated from the Lineweaver–Burk
plot) (Figure 2C). We also determined the pH dependence (from
pH 4 to 10) for metabolic O-methylation of L-DOPA by the
cytosol from these three human livers (Figure 2D). Based on these
measurements, a common reaction condition was devised for
COMT-mediated O-methylation reactions, which included an
incubation time of 10 min, an enzyme concentration of 0.25 mg/
mL, a [
3H-methyl]AdoMet concentration of 250 mM, and a
substrate concentration range from 0.1 to 25 mM.
To determine the modulating effect on L-DOPA methylation in
vitro, the methylation reaction was carried out in the co-presence of
varying concentrations of EGCG. EGCG inhibited the COMT-
mediated O-methylation of L-DOPA in a concentration-depen-
dent manner (Figure 3A), with an average IC50 of 0.36 mM, and a
near complete inhibition was seen at 5 mM EGCG. The strong
inhibition of L-DOPA O-methylation by EGCG was measured in
duplicates for each of the human liver cytosolic samples (HL4C,
HL8C and HL9C), and consistent results were obtained.
In addition, we have also tested the effect of the green tea
polyphenol (GTP) extract and the black tea polyphenol (BTP)
extract. Both GTP and BTP extracts strongly inhibited the
COMT-mediated O-methylation of L-DOPA in a concentration-
dependent manner (Figure 3B). The GTP extract had a slightly
stronger inhibition than the BTP extract, partly due to the
presence of higher concentrations of EGCG in the GTP extract
than in the BTP extract (43.7% vs. 16.2%) [18]. Taken together,
these results show that the crude tea extracts and EGCG (a
quantitatively-major tea polyphenol) could function as effective
inhibitors of human COMT-mediated O-methylation of L-DOPA
in vitro.
In vivo modulation of L-DOPA methylation
First, we conducted an experiment to determine the suitable
doses of L-DOPA + carbidopa for studying L-DOPA methylation
in vivo. After oral administration of L-DOPA alone (at 20 mg/kg)
or L-DOPA + carbidopa (at 20 + 5 mg/kg), there was a rather
rapid, short-lasting increase in the plasma L-DOPA level
(estimated plasma half-life of approximately 1 h) (Figure 4A). In
contrast, the level of 3-OMD increased much slower than that of
L-DOPA, and it remained elevated for several hours (Figure 4B),
as reported earlier [19,20]. The total dopamine level in rat
striatum was not increased by treatment with L-DOPA alone but
was slightly increased at 2 and 3 h after the combined L-DOPA +
carbidopa treatment (Figure 4C). Markedly higher striatal 3-
OMD level was also observed in animals jointly treated with L-
DOPA + carbidopa (Figure 4D). Based on these measurements,
we chose to use the combined dosing regimen (20 mg/kg L-
DOPA +5 mg/kg carbidopa), because L-DOPA methylation
under this condition became far more pronounced in both the
Figure 1. Human COMT-mediated O-methylation of L-DOPA (left panel), which results in the formation of two monomethylated
products. It is hypothesized that (-)-epigallocatechin-3-gallate (EGCG, structure shown in the right panel) may serve as a naturally-occurring inhibitor
of human COMT-mediated O-methylation of L-DOPA in vivo. In addition, owing to its strong antioxidant activity, it is hypothesized that this tea
polyphenol may have additional neuroprotective effects in vivo.
doi:10.1371/journal.pone.0011951.g001
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more suitable for assessing the effect of EGCG on L-DOPA
methylation in vivo.
An earlier study showed that EGCG when used at the daily oral
dose of up to 500 mg/kg for 13 weeks was not toxic in rats [21].
Similarly, we observed in our pilot experiments that oral
administration of EGCG alone at up to 400 mg/kg did not
produce any detectable neuronal damage (data not shown).
Therefore, we chose to use oral administration of EGCG at 100
and 400 mg/kg in the present study, which was given 2 h before
the L-DOPA/carbidopa administration. Under this experimental
condition, the plasma L-DOPA level was not significantly affected
by oral administration of 100 or 400 mg/kg EGCG (Figure 5A),
whereas a modest decrease in plasma 3-OMD level was observed
in animals treated with 400 mg/kg EGCG, but not in animals
treated with 100 mg/kg EGCG (Figure 5B). Oral administration
of 400 mg/kg EGCG also slightly increased the striatal dopamine
level (P,0.05) at 2 h after L-DOPA/carbidopa administration,
but not at 6 h (Figure 5C). The striatal dopamine level was not
significantly changed at any time points in rats co-treated with
100 mg/kg EGCG. Similarly, while the striatal 3-OMD level was
significantly reduced in animals co-treated with 400 mg/kg
EGCG at both 2 and 6 h after L-DOPA/carbidopa administra-
tion, its level was not changed in animals co-treated with 100 mg/
kg EGCG (Figure 5D).
In vitro protection against neuronal oxidative stress and
cell death
To investigate the protective effect of EGCG against oxidative
stress-associated neuronal cell death, the HT22 cells, an
immortalized mouse hippocampal neuronal cell line that is
sensitive to glutamate-induced oxidative cytotoxicity [22], was
used as an in vitro model. As expected, the cell viability was reduced
by 40% after 12-h exposure to 5 mM glutamate. Co-treatment of
Figure 2. Dependence of the in vitro O-methylation of L-DOPA on incubation time (A), cytosolic protein concentration (B), AdoMet
concentration (C), and incubation pH (D). The incubation mixture consisted of 10 mM L-DOPA substrate, 250 mM [methyl-
3H]AdoMet
(containing 0.2 mCi) or as indicated (C), 0.25 mg/mL of human liver cytosolic protein (HL4C) or as indicated (B), 1 mM dithiothreitol, and 1.2 mM
MgCl2 in a final volume of 1.0 mL Tris-HCl buffer (10 mM) at pH 7.4 or as indicated (D). The incubations were carried out at 37uC for 20 min or as
indicated (A). Each value is the mean of duplicate determinations (with average variations ,5%).
doi:10.1371/journal.pone.0011951.g002
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PLoS ONE | www.plosone.org 3 August 2010 | Volume 5 | Issue 8 | e11951Figure 3. Inhibition of human liver COMT-mediated O-methylation of L-DOPA by EGCG, the green tea polyphenol (GTP) extract,
and the black tea polyphenol (BTP) extract. The incubation mixture consisted of 10 mM L-DOPA, 250 mM[
3H-methyl]AdoMet (containing
0.2 mCi), 0.25 mg/mL of human cytosolic protein, 1 mM dithiothreitol, 1.2 mM MgCl2, and a dietary inhibitor (concentration as indicated) in a final
volume of 0.25 mL Tris-HCl buffer (10 mM, pH 7.4). Incubations were carried out at 37uC for 10 min. Each point is the mean of duplicate
determinations (with average variations ,5%).
doi:10.1371/journal.pone.0011951.g003
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EGCG reduced glutamate-induced cell death in a concentration-
dependent manner (Figure 6A). To probe the mechanism of
EGCG’s neuroprotective effect, we determined the effect of
EGCG on the transcriptional activity of NF-kB in HT22 cells
treated with glutamate. As shown in Figure 6B, the transcrip-
Figure 4. Comparison of the concentrations of the plasma L-DOPA (A), plasma 3-OMD (B), striatal dopamine (C), and striatal 3-OMD
(D) in rats. Blood samples were collected from the tail vein at 0.5, 1, 2, 3, 4 and 6 h after oral administration of L-DOPA (20 mg/kg) alone or L-DOPA +
carbidopa (20 +5 mg/kg) (N=3 for each group). The vehicle group received water administration only. Striatal tissues were collected at indicated
time points. Vertical bars indicate the standard deviations (S.D.). * P,0.05 compared to the vehicle group.
doi:10.1371/journal.pone.0011951.g004
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PLoS ONE | www.plosone.org 5 August 2010 | Volume 5 | Issue 8 | e11951Figure 5. Effect of orally-administered EGCG on the methylation of L-DOPA in rats. A. Plasma L-DOPA concentrations. B. Plasma 3-OMD
concentrations. C. Striatal dopamine concentrations. D. Striatal 3-OMD concentrations. Rats (N=3 for each group) were orally administered 100 or
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Luc reporter gene was increased after treatment with 5 mM
glutamate for 24 h, but this increase was significantly suppressed
by co-treatment with 40 mM EGCG. Notably, our recent study
also showed that the intracellular ROS accumulation in
glutamate-treated HT22 cells was time-dependent, with a peak
occurring at approximately 8 h after glutamate treatment [22]. As
shown in Figure 6C and 6D, co-treatment of these cells with
EGCG strongly suppressed the intracellular ROS accumulation at
8 h after treatment with 5 mM glutamate. Taken together, these
data suggest that EGCG’s antioxidant activity contributes to the
reduction of intracellular ROS accumulation and subsequent NF-
kB activation.
In vivo protection against kainic acid-induced neuronal
damage
Next, we assessed the neuroprotective effect of orally-adminis-
tered EGCG in vivo using the kainic acid-induced rat hippocampal
injury model. The kainic acid-induced selective neuronal damage
in rat hippocampus [23] has been a commonly-used in vivo model
for excitotoxic neuronal damage [24]. Mechanistically, oxidative
stress has been identified as a major mechanism for kainic acid-
induced hippocampal neurotoxicity in this animal model [25,26].
EGCG was orally administered 30 min before the intracer-
ebroventricular (i.c.v.) injection of kainic acid (1 mL of the 1 mg/
mL solution) into the right lateral ventricle, and the rat was
sacrificed 24 h later. All rats that received the i.c.v. injection of
kainic acid produced characteristic seizures (such as staring,
immobility, and subsequent wet-dog shake), and these effects were
generally thought to be due to an over-stimulation of the
excitotoxic glutamate receptors by kainic acid. Latency to the
first appearance of clearly-defined wet-dog shakes after kainic acid
injection was recorded as the seizure latency. In animals receiving
both EGCG and kainic acid, no notable differences in latency to
the first wet-dog shakes were observed (54.169.0 min for rats
treated with kainic acid alone vs. 48.469.1 min for rats treated
with EGCG + kainic acid). Here the lack of an appreciable effect
of EGCG suggests that this tea polyphenol does not interfere with
kainic acid’s ability to bind and activate the excitotoxic glutamate
receptors in rat hippocampal neurons.
Additional histological analysis of the damaged brain regions at
24 h post kainic acid injection showed widespread shrinkage of
neuronal cell bodies as well as formation of peri-neuronal vacuoles
in the CA3 region (H/E staining, Figure 7A). In contrast to the
CA3 region, the condensation of neuronal cell bodies and
vacuolation of neurons in the CA1 region was not observed at
24 h after kainic acid treatment (Figure 7A). EGCG treatment
significantly reduced the shrinkage of neuronal cells and also the
formation of vacuoles in the CA3 region in a dose-dependent
manner. The extent of neurodegeneration in the hippocampus was
also assessed using the Fluoro-Jade B staining. In kainic acid-
treated rats, there was a marked decline in the overall number of
neurons as well as an increased number of degenerating neurons
in the CA3 region (Figure 7A, 7B). In comparison, kainic acid-
induced hippocampal neuronal cell death was markedly reduced
in EGCG-treated animals (Figure 7A, 7B). Similarly, the density
of GFAP-positive astrocytes, a parameter that reflects functional
changes of astrocytes in damaged regions, was increased following
kainic acid injection, but it was markedly reduced in EGCG-
treated rats (Figure 7C). These data suggest that EGCG may also
suppress the early response of hippocampal astrocytes.
To assess whether the antioxidant effect of EGCG is a potential
mechanism for its in vivo neuroprotective effect, the plasma NO2
2/
NO3
2 levels were measured as a marker of oxidative stress. The
plasma NO2
2/NO3
2 level was significantly elevated at 24 h after
kainic acid injection compared to control animals, but this increase
was drastically reduced in animals treated with EGCG
(Figure 7D).
Discussion
In the present study, we sought to investigate the beneficial
effects of EGCG, a well-known tea polyphenol, on L-DOPA O-
methylation and oxidative neurodegeneration in an effort to
explore the intriguing possibility that certain dietary polyphenols
may serve as effective COMT inhibitors as well as neuroprotective
agents. We found that EGCG, a quantitatively-abundant
polyphenol contained in tea beverages, can strongly inhibit L-
DOPA methylation in vitro catalyzed by human liver cytosolic
COMT (Figure 3A), with a high inhibition potency (IC50 of 0.1–
0.6 mM). The molecular mechanism underlying EGCG’s high-
potency inhibition of human COMT has been recently investi-
gated by using computational molecular modeling approaches
[27]. It was suggested that EGCG can bind with a high affinity to
the catalytic site of human COMT. Theoretically, EGCG
functions as a tight-binding competitive COMT inhibitor, but
because of the high-affinity nature of its binding to the enzyme, it
actually functions like a potent non-competitive inhibitor (i.e.,
functionally similar to an irreversible competitive inhibitor).
When normal rats (treated with L-DOPA + carbidopa) were
given an oral administration of EGCG (at 400 mg/kg), their 3-
OMD levels in circulation and striatum were reduced by
approximately 30%, clearly reflecting an in vivo inhibition of L-
DOPA methylation. By contrast, only a very small increase (no
statistical significance) in L-DOPA plasma concentrations was
observed in these animals (Figure 5). Notably, our observation of
a strong reduction of 3-OMD level but a lack of meaningful
increase in L-DOPA plasma concentration in rats treated with L-
DOPA + carbidopa + EGCG was similar to the earlier
observations with tolcapone or entacapone in rats [28–31] or
human subjects [32–34] that were also treated with L-DOPA +
carbidopa. For instance, it was observed that while tolcapone or
entacapone at relatively lower doses (3 and 7.5 mg/kg) effectively
reduced the circulating and striatal levels of 3-OMD in normal
rats co-treated with L-DOPA + carbidopa, their effect on the
circulating and striatal L-DOPA levels was much smaller [28,31],
as seen in the present study with EGCG. The reason for the lack of
a greater increase in striatal dopamine content in normal rats likely
is because its concentration is under a tight regulation to be kept
within a narrow normal range. It is possible that in the striatum of
PD patients where there is a severe local dopamine deficiency, a
greater increase in dopamine concentration likely will be seen
when they are co-treated with EGCG. This explanation was
supported by an earlier clinical study showing a positive
correlation between the degree of striatal dopamine deficiency
and the capacity of L-DOPA to increase synaptic dopamine
content in PD patients [35].
The observed weaker in vivo potency and efficacy of EGCG in
inhibiting L-DOPA methylation (based on inhibition of 3-OMD
400 mg/kg of EGCG 2 h before oral administration of L-DOPA + carbidopa (20+5 mg/kg). The vehicle group received water administration only.
* P,0.05 compared to the vehicle treatment group.
# P,0.05 compared to the L-DOPA + carbidopa group.
doi:10.1371/journal.pone.0011951.g005
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PLoS ONE | www.plosone.org 7 August 2010 | Volume 5 | Issue 8 | e11951Figure 6. Protective effects of EGCG against glutamate-induced HT22 cell death. A. Cell viability. B. Transcriptional activity of NF-kB.
C. ROS generation. D. Percentage (%) of H2-DCF-DA-positive cells. HT22 cells were treated with 5 mM glutamate and/or EGCG at indicated
concentrations. Cell viability, transcriptional activity of NF-kB, NF-kB subcellular localization, and ROS accumulation were determined as described in
the Materials and Methods. The experiment was repeated at least 3 times. DAPI staining was employed as a nuclear counter stain. Vertical bars
indicate standard deviation (S.D., N=5). * P,0.05 compared to glutamate-treated group.
doi:10.1371/journal.pone.0011951.g006
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PLoS ONE | www.plosone.org 8 August 2010 | Volume 5 | Issue 8 | e11951Figure 7. Effect of orally-administered EGCG on kainic acid-induced rat hippocampal injury. A. Histopathological and histochemical
analyses of the brain tissues. B. Number of degenerating neurons based on the Fluoro-Jade B staining. C. Expression levels of GFAP-immunoreactive
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rats (only approximately 2%) [36,37]. It is known that rodents, in
general, have a much higher ability to metabolically dispose
phytochemicals than do humans. Because of this reason, the
effective doses of EGCG required for PD patients may be
considerably smaller than what were used in the present study.
Consistent with this suggestion, earlier human studies [38,39]
showed that the circulating concentrations after oral administra-
tion of 800 mg EGCG are higher than its effective IC50
concentrations required for inhibiting L-DOPA methylation in
vitro. Therefore, it is possible that oral administration of EGCG
may readily reach therapeutically-effective concentrations needed
for inhibiting L-DOPA methylation in PD patients.
An earlier study using
3H-EGCG showed that this tea
polyphenol can pass through the blood-brain-barrier and are
present in the central nervous system [40]. Our observation of a
significant reduction in the striatal 3-OMD level in EGCG-treated
rats is thought to be due to EGCG’s direct inhibition of the central
COMT-mediated L-DOPA methylation. It is of interest to point
out that the reduction in striatal 3-OMD level may aid in reducing
the side effects associated with the long-term L-DOPA/carbidopa
therapy. It is known that about 50% of PD patients chronically
receiving L-DOPA-based therapy would develop complications
within the first 5 years of treatment, which often include severe
motor fluctuations (wearing-off phenomenon) and dyskinesia
[2,41,42]. The exact cause of these adverse effects has not been
established at present. 3-OMD, a major metabolite of L-DOPA
formed in peripheral and brain tissues, was detected at high levels
in the plasma as well as cerebral spinal fluid of PD patients treated
with L-DOPA/carbidopa [43,44], and the plasma levels of 3-
OMD in patients with dyskinesia were significantly higher than
those from patients without dyskinesia [45]. Mechanistically, it has
been suggested that 3-OMD may interfere with the utilization of
L-DOPA in the rat brain, and it may also cause neuronal damage
via oxidative stress. In addition, it has been suggested that 3-OMD
accumulation following long-term L-DOPA administration might
contribute to the progression of neurodegeneration in PD patients
[13,46]. Based on these considerations, it is suggested that the
ability of EGCG to markedly reduce 3-OMD levels in the
periphery and particularly in the striatum would be beneficial for
reducing the neuronal toxicity associated with high levels of 3-
OMD.
A number of studies have examined the neuroprotective
potential of EGCG [47–49], which is an antioxidant. It was
shown that EGCG can inhibit neuronal damage induced by nitric
oxide and b-amyloid [47–49]. However, a recent study also
reported that EGCG does not protect against 6-hydroxydopa-
mine-induced loss of nigral dopaminergic neurons in rats [50]. In
the present study, we sought to further examine the protective
effect of EGCG against oxidative degeneration in hippocampal
neurons. This brain region is of considerable interest because PD
patients are associated with a 6-fold higher risk of developing
dementia, a clinical condition characterized by hippocampal
atrophy [51,52]. The HT22 cells, an immortalized mouse
hippocampal neuronal cell line, were used in this study as an in
vitro model. Mechanistically, glutamate induces neurotoxicity in
these neuronal cells via inhibition of N-acetyl-cysteine uptake,
which decreases cellular glutathione levels and ultimately causes
oxidative stress and cell death [22,53,54]. We found that EGCG,
when present at relatively high concentrations (30–40 mM),
exerted a strong neuroprotective effect against glutamate-induced
oxidative stress in HT22 cells, which is in agreement with an
earlier study [55]. To understand the mechanism by which EGCG
protects neurons from oxidative damage, we examined its effect on
cellular ROS accumulation and NF-kB activation. Earlier studies
have shown that cellular oxidative stress caused by ROS
accumulation can result in NF-kB activation [56]. We found that
EGCG’s neuroprotective effect in glutamate-treated HT22 cells is
associated with reductions in ROS accumulation and NF-kB
transcriptional activity (Figure 6). Notably, induction of oxidative
stress is also recognized as a major mechanism in kainic acid-
induced selective hippocampal damage in rats [23–25]. Using this
in vivo model, therefore, we further demonstrated that a single oral
administration of EGCG could effectively reduce kainic acid-
induced hippocampal neuronal death (Figure 7). In addition, we
observed that kainic acid could induce early astrocyte activation in
the hippocampal CA3 region, which is in agreement with earlier
reports [23,57]. Co-treatment with EGCG significantly reduced
the number of GFAP-positive astrocytes (Figure 7A). Collectively,
these data suggest that EGCG exerts its in vivo protection against
chemically-induced neuronal oxidative damage jointly through
promotion of neuronal survival and suppression of glial activation.
These effects likely will be beneficial for reducing hippocampal
impairments in PD patients as well as in reducing neural
complications associated with the long-term L-DOPA-based
therapy.
It is of considerable interest to note that recent epidemiological
studies suggest that regular tea or coffee drinking is associated with
a reduced risk of PD [16,17]. The potential beneficial effects of
EGCG (and possibly other tea and coffee polyphenolic com-
pounds) on brain catecholamine metabolism and neuronal survival
as observed in this study shed a mechanistic light on these
intriguing epidemiological observations. Although the daily intake
of EGCG through regular tea drinking may not reach a
therapeutically effective concentration, it should be noted that
tea and coffee also contain many other polyphenolic antioxidants.
The collective neuroprotective effect exerted by these polyphenolic
compounds could be significant. Moreover, many of these dietary
compounds (such as catechin, quercetin, and caffeic acid) also
contain the same catecholic structures as does L-DOPA, which
make them good substrates and also effective inhibitors of COMT
[11,12,18,27,36,58]. Theoretically, a collective inhibition of
COMT-mediated O-methylation of endogenous catecholamines
(including dopamine and L-DOPA) by these dietary polyphenols
could be quite significant in the human body. In partial support of
this suggestion, it is known that drinking tea and coffee is
associated with a number of physiological effects in humans, such
as increased heart rate and contractility, increased urination, and
strong central nervous system stimulation. These effects are all
known to be associated with elevated levels of endogenous
catecholamines. While some of these effects associated with tea
and coffee often are conveniently attributed to the small amounts
of theophylline and caffeine contained in them, the contribution of
COMT inhibition has also been suggested in recent years [59,60].
In summary, we demonstrated in this study that EGCG is an
inhibitor of COMT-mediated O-methylation of L-DOPA both in
vitro and in vivo. The significant reduction of 3-OMD by EGCG
may increase L-DOPA bioavailability in the central nervous
(IR) astrocytes in the CA3 region. D. Plasma NO2
2/NO3
2 levels. Rats (N=3 for each group) were orally administered 100 or 400 mg/kg of EGCG
30 min before kainic acid injection. Kainic acid (1 mL of 1 mg/mL solution) was injected into the right lateral ventricle (anterior/posterior, 21.0; rostral,
1.6; dorsal/ventral, 4.5) using a microliter syringe. * P,0.05 compared to kainic acid-treated group.
doi:10.1371/journal.pone.0011951.g007
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with elevated levels of 3-OMD. In addition, EGCG also has a
strong protective effect against hippocampal neuronal oxidative
stress and cell death both in vitro and in vivo. Taken together, these
observations provide an example that some of the dietary
polyphenolic compounds may have highly-desirable dual benefi-
cial effects in PD patients that are treated with L-DOPA/
carbidopa. Although EGCG per se may not be the most ideal
dietary compound for this particular therapeutic purpose (in light
of its relatively low in vivo bioavailability), these findings,
nevertheless, provide impetus to search for other dietary
polyphenolic compounds (e.g., bioflavonoids and coffee polyphe-
nols) that not only have similar dual beneficial effects in PD but
also have more desirable in vivo bioavailability. Also, the results
from this study raise the possibility for chemically modifying the
structure of EGCG to yield safe derivatives that may have
markedly improved in vivo bioavailability but still retain similar
neuronal beneficial effects in PD.
Materials and Methods
Chemicals
EGCG, L-DOPA, carbidopa, 3-OMD, dopamine, 3,4-dihy-
droxybenzylamine hydrobromide (DHBA), glutamate, kainic acid,
2’,7’-dichlorofluorescein diacetate, ethylenediaminetetraacetic ac-
id (EDTA) and nitrate reductase were obtained from Sigma
Chemical Co. (St. Louis, MO, USA). The black tea polyphenol
(BTP) extract and the green tea polyphenol (GTP) extract were
gifts from Thomas J. Lipton Company (Englewood Cliffs, NJ). The
compositions of the BTP and GTP extracts were described earlier
[18]. [
3H-methyl]AdoMet (specific activity =11.2-13.5 Ci
mmol
21, purity .97%) was purchased from New England
Nuclear Research Products (Boston, MA, USA). The plasmid
pNF-kB-Luc carrying a firefly luciferase cDNA driven by 56NF-
kB-binding sites was purchased from Stratagene (La Jolla, CA,
USA). All other reagents used in this study were obtained from
standard suppliers and were of analytical grade (in purity) or
better.
In vitro modulation of COMT-catalyzed L-DOPA
methylation by EGCG or crude tea extracts
The collection of human liver samples (approved by the
Institutional Review Boards (IRBs) of the University of South
Carolina, Columbia, SC, and the UMDNJ-Robert Wood Johnson
Medical School, New Brunswick, NJ, USA) and the methods for
preparation of cytosols from these tissues were described in detail
earlier [12]. For assaying the in vitro O-methylation of L-DOPA by
human liver cytosolic COMT, the incubation mixture usually
consisted of 10 mM L-DOPA as substrate, 250 mM[
3H-methy-
l]AdoMet (containing 0.2 mCi) as the methyl group donor,
0.25 mg/mL of human liver cytosolic protein as the source of
COMT, 1 mM dithiothreitol, 1.2 mM MgCl2, and the dietary
inhibitor (EGCG, GTP extract, or BTP extract) in a final volume
of 0.25 mL Tris-HCl buffer (10 mM, pH 7.4). Incubations were
carried out at 37uC for 10 min. The methyl ethers of L-DOPA
were measured by using HPLC as described below. Each data
point was the mean of duplicate determinations (with average
variations ,5%).
Study of the in vitro protective effect of EGCG against
neuronal oxidative stress and cell death
Glutamate-sensitive HT22 murine hippocampal neuronal cells
(a gift from Dr. David Schubert at Salk Institute, La Jolla, CA)
were maintained in DMEM supplemented with 10% (v/v) FBS
and antibiotics (penicillin-streptomycin), and incubated at 37uC
under 5% CO2. Cells were subcultured once every 2 days. The
cells were seeded in 96-well plates at a density of 5000 cells per
well. The stock solution of glutamate (1 M in DMEM without
serum) and EGCG (20 mM in 100% ethanol) was diluted in the
culture medium immediately before addition into each well at
desired final concentrations, and the treatment lasted for up to
12 h.
The MTT assay was used for assessment of cell viability as
described in our recent study [22]. The relative cell density was
expressed as percentage of the control that was not treated with
glutamate. For detection of transcriptional activity of NF-kB,
HT22 cells in 24-well culture plates were transfected with 0.05 mg
pNF-kB-Luc plasmid using Lipofectamine 2000 reagent (Invitro-
gen, Carlsbad, CA, USA). Twenty-four h after transfection, cells
were treated with 5 mM glutamate and/or 40 mM EGCG for 8 h.
Then cells were harvested and the luciferase activity was
determined by TD-20/20 Luminometer (Turner Designs, Sunny-
vale, CA). Firefly luciferase activity was normalized to the protein
concentration.
The accumulation of ROS in HT22 cells with or without
glutamate treatment was detected using the 2’,7’-dichlorofluor-
escein diacetate (H2-DCF-DA) method. H2-DCF-DA (1 mM) was
added to each well, and incubated for 20 min at 37uC. Then the
liquid was removed and PBS was added. Intracellular ROS
accumulation was observed and photographed under a fluores-
cence microscope (AXIO, Carl Zeiss Corporation, Germany).
Study of the in vivo modulation of the O-methylation of
L-DOPA by EGCG in rats
All procedures involving the use of live animals as described in
this study were approved by the Institutional Animal Care and
Use Committee (IACUC) of the University of Kansas Medical
Center, and strictly followed the guidelines for humane care of
animals set forth by the National Institutes of Health. Male
Sprague-Dawley rats, weighing 250–270 g, were purchased from
Harlan (Indianapolis, IN) and kept in a plastic bottomed cage with
a 12-h light/12-h dark cycle, under controlled room temperature
(at 25uC) and humidity (60%). They were allowed free access to
laboratory pellet chow and water. After arrival, the animals were
allowed to acclimate to the new environment for one week before
they were used in the experimentation. Rats were randomly
divided into various experimental groups (N=3 to 5) with no
significant difference in average body weights. The animals were
orally administered 100 or 400 mg/kg EGCG 2 h before
administration of L-DOPA and carbidopa (20 and 5 mg/kg,
p.o.). Control rats received the same oral administrations of vehicle
only. Blood samples were collected from the tail vein with light
anesthesia (isoflurane inhalation) at 0.5, 1, 2, 3, 4 and 6 h after L-
DOPA + carbidopa administration. About 100 mL blood was
drawn, collected in heparin-coated tube, and plasma was obtained
from rapid centrifugation and immediately frozen at 280uC until
analysis (within 14 days). At 2 and 6 h after blood collection, rats
were euthanized with CO2 followed by decapitation. The striatal
regions of the brain were dissected, weighed, and kept at 280uC
until analysis.
Plasma L-DOPA and its metabolites were measured using a
method described previously [61] with minor modifications.
Plasma samples (50 mL) from each rat were spiked with 5 mL
internal standard (DHBA, 100 mM). To precipitate proteins,
20 mL of 1.2 M perchloric acid was added. Tubes were mixed,
placed on ice for 10 min, and centrifuged for 4 min at 1250 g at
4uC. Aliquots (30 mL) of the supernatant were added to 60 mL
potassium citrate buffer (0.2 M, pH 3.8) to precipitate the
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10 min, centrifuged for 4 min at 1250 g at 4uC, and then an
aliquot of the supernatant was injected onto the HPLC for analysis
of composition.
Concentrations of 3-OMD and dopamine in striatum were
measured by HPLC with electrochemical detection according to a
previously described method [62]. Briefly, the thawed tissues were
homogenized using PowerGen 700 (Fisher Scientific, Pitsburgh,
PA, USA) in 0.4 M perchloric acid, and the homogenates were
centrifuged and filtered for HPLC analysis.
The HPLC system consisted of a Shimadzu pump (LC-10AT
model), an electrochemical detector (Coulochem III, ESA
Bioscience, Chelmsford, MA, USA), and a HR-80 C18 reverse-
phase column (3 mm, 8064.6 mm, ESA Bioscience). The mobile
phase consisted of 50 mM sodium phosphate, 1 mM sodium
dodecyl sulfate, 0.67 mL triethylamine, 13.3 mM EDTA, and 8%
acetonitrile in water, adjusted to pH 3.0 with phosphoric acid.
Before use, the mobile phase was filtered through 0.45 mm (pore
size) filter (Millipore, Bedford, MA, USA), and degassed under
vacuum. An isocratic elution at a flow rate of 1 mL/min was used.
L-DOPA and its metabolites were identified by comparing their
retention times with those of standard compounds. Concentrations
were calculated from the peak height with the aid of an internal
standard (DHBA). Linearity of the detector responses were tested
for all catecholamines, and the coefficients of correlation for all
standards were .0.999. The relative standard deviation for the
intra-day repeatability was below 5%, representing good precision
of the analytical method used.
Study of the in vivo protective effect of EGCG against
kainic acid-induced hippocampal injury in rats
In these experiments, male Sprague-Dawley rats were
randomly divided into multiple experimental groups (N=3 to
5 per group), with very similar average body weight for each
group. Animals were orally administered 100 or 400 mg/kg
EGCG 30 min before kainic acid injection. Kainic acid (1 mLo f
1 mg/mL solution) was injected into the right lateral ventricle
(anterior/posterior, 21.0; rostral, 1.6; dorsal/ventral, 4.5) using
a microliter syringe under anesthesia with ketamine and
xylazine (50 and 5 mg/kg, s.c.). The needle was withdrawn
5 min later and scalp was sutured. Experimental control rats
were injected with 1 mL of saline instead of kainic acid [63].
Before collecting the brain tissue for analysis (24 h after kainic
acid injection), the animals received ketamine and xylazine (50
and 5 mg/kg, s.c.) for anesthesia, and then perfused with 0.1 M
neutral phosphate buffered 10% formalin (4% formaldehyde)
via the ascending aorta, while the descending aorta was clamped
off.
The collected brain tissues were postfixed overnight in the same
fixative solution. After cryoprotection in 30% sucrose/phosphate
buffer, the tissues were frozen in liquid nitrogen and sectioned
serially (30 mm) through the entire brain. The sections were
collected in 0.1 M neutral phosphate buffer, mounted on slides,
then air-dried on a slide warmer at 50uC for at least half an hour,
and stained with hematoxylin and eosin (H/E) for histopatholog-
ical analysis.
Fluoro-Jade B staining was performed by following the protocols
described by Schmued and Hopkins [64] with minor modifica-
tions. Briefly, the slides were transferred to a solution of 0.06%
potassium permanganate for 10 min, preferably on a shaker to
insure consistent background suppression between sections. The
staining solution was prepared from a 0.01% stock solution of
Fluoro-Jade B that was prepared by adding 10 mg of the dye
powder to 100 mL of distilled water. After 20 min in the staining
solution, the slides were rinsed and placed on a slide warmer until
they were fully dry. The cell bodies of Fluoro-Jade B-positive
neurons were viewed under a fluorescence microscope. The
number of stained neurons was counted in the obtained images
using the Axiovision image analysis software (Carl Zeiss, Inc.,
Thornwood, NY). For analysis of the hippocampus, the total
number of stained neurons was counted in the dorsal hippocampal
region (between 21.5 and 22.5 mm from bregma) by using three
sections from each rat.
Since astrocyte activation, as evidenced by up-regulation of
glial fibrillary acidic protein (GFAP), often was present in
damaged neuronal regions, tissue sections were also incubated
successively with rabbit monoclonal anti-GFAP antibody (1:800,
Sigma-Aldrich), goat-biotinylated-conjugated polyclonal anti-
rabbit antibody (1:250, Vector Laboratories, CA, USA), and
horseradish-peroxidase conjugated avidin-biotin complex (Vector
Laboratories). Sections were then exposed to DAB substrate kit
(Vector Laboratories) for detection. To perform quantitative
analysis of GFAP immunostaining, 3–4 sections per animal were
selected and images were captured and analyzed using Axiovision
image analysis software. One field (100 mm6100 mm) in each
slide within the midpoint of hippocampal CA3 regions was
selected for quantification, and the intensity of GFAP immuno-
reactivity was evaluated according to the relative optical density
value.
The plasma nitrite/nitrate (NO2
2/NO3
2) level, a commonly-
used ROS index in vivo, was determined by converting NO3
2 to
NO2
2 with nitrate reductase, followed by addition of Griess
reagent for colourimetric measurement of NO2
2 concentrations
[65].
Data analysis
Results were expressed as means 6 SD. The statistical
significance was determined by analysis of variance (ANOVA)
followed by a multiple comparison test with a Bonferroni
adjustment. P values of less than 0.05 were considered statistically
significant.
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